Video

Dr. Abou-Alfa Discusses Results of the CELESTIAL Trial in Advanced HCC

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma during the 2018 Gastrointestinal Cancers Symposium.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma (HCC) during the 2018 Gastrointestinal Cancers Symposium.

The CELESTIAL trial compared cabozantinib (Cabometyx) versus placebo in patients with advanced HCC who have received prior sorafenib (Nexavar). Results from this randomized phase III trial showed a median overall survival (OS) of 10.2 months for the cabozantinib arm versus 8 months for the placebo arm (HR 0.76, 95% CI, 0.63-0.92; P = .0049)—which is clinically and statistically significant, says Abou-Alfa. Additionally, the median progression-free survival was 5.3 months for cabozantinib compared with 1.9 months with placebo (HR, 0.44; 95% CI, 0.36-0.52; P <.001).

These results indicate that cabozantinib showed an improvement in OS when administered after treatment with sorafenib. Abou-Alfa says that these findings provide a durable and well-tolerated second-line option for patients with advanced HCC.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity